FXR (NR1H4) Modulating Compounds

A compound according to Formula (I):

• wherein:
• Q is phenylene or pyridylene, each of which is optionally substituted with one or two substituents independently selected from halogen, methyl, C1-4-alkoxy, halo-C1-4-alkoxy, —CH2F, —CHF2, and —CF3;
• Y is N or CH;
• A is pyridylene or phenylene, each of which is optionally substituted with one or two groups independently selected from halogen, C1-4-alkoxy, halo-C1-4-alkoxy, C1-4-alkyl, and halo-C1-4-alkyl;
• Z is isoxazole substituted with R1 or pyrazole substituted with R1;
• R1 is C1-4-alkyl or C3-6-cycloalkyl, wherein
• said C1-4-alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C1-3-alkoxy, and fluoro-C1-3-alkoxy, and
• said C3-6-cycloalkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C1-3-alkyl, fluoro-C1-3-alkyl, C1-3-alkoxy, and fluoro-C1-3-alkoxy;
• R2 and R3 are independently selected from hydrogen, halogen, methoxy, —CF3, —CHF2, —CH2F, —OCH2F, —OCHF2, —OCF3, and methyl;
• R4 is —CO2R5 or —C(O)NR5R6;
• R5 is hydrogen, C1-6-alkyl, or halo-C1-6-alkyl;
• and
• R6 is hydrogen or C1-6-alkyl, wherein said C1-6-alkyl is optionally substituted with 1 to 6 substituents independently selected from halogen, —SO3H, and —CO2H;
• or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof.